Fatty acid metabolism is known to support tumorigenesis and disease progression as well
as treatment resistance through enhanced lipid synthesis, storage and catabolism. More …

Lipid metabolic reprogramming is an established trait of cancer metabolism that guides
response and resistance to antitumoral therapies. Enhanced lipogenesis, increased lipid …

Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the
orchestration of metabolic pathways in regulating ferroptosis will provide new insights into …

HOXB13, a homeodomain transcription factor, critically regulates androgen receptor (AR)
activities and androgen-dependent prostate cancer (PCa) growth. However, its functions in …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

The androgen receptor (AR) is the key oncogenic driver of prostate cancer, and despite
implementation of novel AR targeting therapies, outcomes for metastatic disease remain …

Prostate cancer (PCa) is the most common cancer in men, and more than 10% of men will
be diagnosed with PCa during their lifetime. Patients that are not cured with surgery or …

Current endocrine therapy for prostate cancer (PCa) mainly inhibits androgen/androgen
receptor (AR) signaling. However, due to increased intratumoural androgen synthesis and …

Tumor metabolism supports the energetic and biosynthetic needs of rapidly proliferating
cancer cells and modifies intra-and intercellular signaling to enhance cancer cell invasion …

Mining of integrated public transcriptomic and ChIP-Seq (cistromic) datasets can illuminate
functions of mammalian cellular signaling pathways not yet explored in the research …